
| 2014 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2010 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2014 | 0 | 5.993.000 | 1.903.100 | 1 | ||
| 2013 | 0 | 5.997.405 | 1.917.800 | 1 | ||
| 2010 | 0 | 2.999.560 | 24.000 | 1 | ||
Total number of partners: 36
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 36
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2014-02-01 | Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months | NEOVANC | participant | 5.993.000 | 12 |
| 2013-12-01 | Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit | CLOSED | participant | 5.997.405 | 10 |
| 2010-11-01 | Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects | ADDUCE | participant | 2.999.560 | 17 |